
Simulect20 mg/vial
Novartis (Bangladesh) Ltd.
Basiliximab is a chimeric (murine/human) monoclonal antibody that is FDA-approved for the following use: Established/approved use: Prophylaxis (prevention) of acute organ rejection in adult and…
Basiliximab is a chimeric (murine/human) monoclonal antibody that is FDA-approved for the following use:
| Dose | Timing |
|---|---|
| 20 mg IV | Within 2 hours before transplant surgery (Day 0) |
| 20 mg IV | 4 days after transplantation (Day 4) |
Total course: two doses. If a severe hypersensitivity reaction or graft loss occurs, the second dose should not be given.
| Body Weight | Dose | Schedule |
|---|---|---|
| Less than 35 kg | 10 mg IV | Day 0 (pre-transplant) and Day 4 (post-transplant) |
| 35 kg or more | 20 mg IV | Day 0 (pre-transplant) and Day 4 (post-transplant) |
Basiliximab is given only by a healthcare professional in a hospital/transplant center, as an intravenous infusion (diluted, over about 20-30 minutes) or as a slow IV bolus injection. It must be administered as part of an overall immunosuppressive regimen and only under the supervision of a physician experienced in transplant immunosuppression, in a facility equipped to manage severe hypersensitivity reactions.
No dose adjustment is established as required for renal or hepatic impairment based on available data; use in these patients requires individualized specialist judgment.
Basiliximab is contraindicated in patients with known hypersensitivity to basiliximab or to any component of the formulation.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.